General MedicationsORALGeneric

NORGESIC FORTE

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

Standard Dose

770MG;60MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview NORGESIC FORTE is listed in Drugs@FDA under application 013416 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE Form and strength TABLET;ORAL - 770MG;60MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAUSCH Submission history Latest submission status date: 2021-04-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview NORGESIC FORTE is listed in Drugs@FDA under application 013416 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE Form and strength TABLET;ORAL - 770MG;60MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAUSCH Submission history Latest submission status date: 2021-04-28 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.